Guggenheim initiated coverage on Genelux with a new price target
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $16.00 | Buy | Lake Street |
| 10/29/2024 | $8.00 | Buy | Guggenheim |
| 8/28/2024 | $10.00 | Buy | ROTH MKM |
| 11/27/2023 | $35.00 | Buy | H.C. Wainwright |
| 9/12/2023 | $40.00 | Buy | Maxim Group |
| 2/15/2023 | $10.00 | Speculative Buy | The Benchmark Company |
Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00
Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00
ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
3 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
8-K - GENELUX Corp (0001231457) (Filer)
424B5 - GENELUX Corp (0001231457) (Filer)
424B5 - GENELUX Corp (0001231457) (Filer)
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. In addition, Genelux has granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of its common s
WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ("Genelux") (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In platinum-relapsed or platinum-refractory advanced SCLC, two of three partial responses (PRs) occurred in the highest dose cohort tested as of the data review cutoff date (tumor shrinkage of ~55% and ~85%), with three PRs out of nine subjects (33%) across all dose cohorts; observed durable response signals and treatment tolerability (Phase 1b/2 SCLC) -- -- In advanced or metastatic recurrent NSCLC, observed anti-tumor activity in initial dose cohort and Olvi-Vec generally wel
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this
WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory
Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were
SC 13G - GENELUX Corp (0001231457) (Subject)
SC 13G/A - GENELUX Corp (0001231457) (Subject)
SC 13G - GENELUX Corp (0001231457) (Subject)